Author: Gale, E.A.
Description: Troglitazone, the first in the thiazolidinedione class of oral hypoglycaemic agents, was launched in the USA in March, 1997. It reached Europe later that year, only to be withdrawn within weeks on the grounds of liver toxicity. Meanwhile it went on to generate sales of over $2 billion in the USA, and caused at least 90 cases of liver failure (70 resulting in death or transplantation) before it was withdrawn in March, 2000. Rosiglitazone and pioglitazone reached the US market in 1999 as first-line agents to be used alone or in combination with other drugs, but in Europe the same dossiers were used one year later to apply for a limited licence as second-line agents restricted to oral combination therapy. How should we use the glitazones? And how did they achieve blockbuster status without any clear evidence of advantage over existing therapy?
Subject headings: Adverse Drug Reaction Reporting Systems; Chromans/administration & dosage/*adverse effects; Diabetes Mellitus, Type 2/*drug therapy; Drug Approval/*legislation & jurisprudence; Drug Therapy, Combination; Drug-Induced Liver Injury/etiology; Europe; Humans; Hypoglycemic Agents/administration & dosage/*adverse effects; Liver Failure/chemically induced; Thiazoles/administration & dosage/*adverse effects; *Thiazolidinediones; United States
Publication year: 2001
Journal or book title: Lancet
Volume: 357
Issue: 9271
Pages: 1870-1875
Find the full text : http://www.sciencedirect.com/science/article/pii/S0140673600049606
Find more like this one (cited by): https://scholar.google.com/scholar?cites=544808733366160543&as_sdt=1000005&sciodt=0,16&hl=en
Type: Journal Article
Serial number: 921